Table 2.

Multivariate Logistic Regression Analysis of Predictors of SGLT‐2 Inhibitor and GLP‐1RA Use in Patients With Diabetes Mellitus

	SGLT‐2 Inhibitor		GLP‐1RA
	Odds Ratio [95% CI]	P Value	Odds Ratio [95% CI]	P Value
Age	0.77 [0.34–1.17]	0.25	0.61 [0.41–0.82]	0.002
Women	0.50 [0.08–3.05]	0.42	1.4 [0.26–7.7]	0.65
Non‐Hispanic White	1.5 [0.56–4.1]	0.37	1.4 [0.17–12.0]	0.70
Non‐Hispanic Black	0.79 [0.33–1.8]	0.58	2.7 [0.43–17.3]	0.26
Any compelling indication	4.2 [1.23–14.8]	0.02	0.97 [0.28–3.3]	0.97

Compelling indications included established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease stage III/A2–3 for SGLT‐2 inhibitors, and established or high‐risk atherosclerotic cardiovascular disease for GLP‐1RAs. GLP‐1RA indicates glucagon like peptide‐1 receptor agonist; and SGLT‐2, sodium glucose transporter‐2.